Evidence map›Paper›PMID 41297163›Full record

ArticleESMO open2025

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.

E Krieghoff-Henning, T Michaeli, T Boch, J Kirchhof, V Haselmann, M Neumaier, W-K Hofmann, J Betge, M Ebert, A Teufel and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

E Krieghoff-HenningDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
T MichaeliDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
T BochDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
J KirchhofDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany; Mannheim Cancer Center (MCC), Center for Clinical Trials, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
V HaselmannInstitute for Clinical Chemistry, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
M NeumaierInstitute for Clinical Chemistry, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
W-K HofmannDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
J BetgeDKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; Junior Clinical Cooperation Unit Translational Gastrointestinal Oncology and Preclinical Models, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Medicine II, Medical Faculty at Mannheim, University of Heidelberg, Mannheim, Germany.
M EbertDepartment of Medicine II, Medical Faculty at Mannheim, University of Heidelberg, Mannheim, Germany.
A TeufelDivision of Hepatology, Division of Bioinformatics, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Clinical Cooperation Unit Healthy Metabolism, Center for Preventive Medicine and Digital Health Baden-Württemberg (CPDBW), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
V AstInstitute for Clinical Chemistry, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
C SauerDepartment of Pathology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
C CotareloDepartment of Pathology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
R LozynskyyDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; German Center for Lung Research (DZL), German Cancer Consortium (DKTK), Heidelberg, Germany.
M JanningDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; German Center for Lung Research (DZL), German Cancer Consortium (DKTK), Heidelberg, Germany.
F MarméDepartment of Gynecology and Obstetrics, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
M SütterlinDepartment of Gynecology and Obstetrics, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
A StreuerDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
F SiegelDepartment of Biomedical Informatics, Mannheim Institute for Intelligent Systems in Medicine (MIISM), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
C BrochhausenDepartment of Pathology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
M CollienneDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; German Center for Lung Research (DZL), German Cancer Consortium (DKTK), Heidelberg, Germany.
D NowakDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
S LogesDepartment of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany; Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany; German Center for Lung Research (DZL), German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: Sonja.Loges@medma.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPanel sequencing, whole-exome sequencing (WES) and whole-genome sequencing (WGS) often uncover therapeutic targets for cancer patients. However, it is still largely unclear to what extent patients directly benefit from broader analyses over panel sequencing alone. MATERIALS AND

methodsWe analyzed the molecular findings and recommendations issued by our molecular tumor board (MTB) in a cohort of patients who had received both a well-established diagnostic panel of medium size (up to 203 genes) and in-house WES, focusing on the number of recommendations that were issued on the basis of WES results only.

resultsOur cohort consisted of 38 patients with advanced cancers, of whom about two-thirds had common and one-third had rare cancers. They received a total of 45 (range 0-4) treatment recommendations overall, of which 29 had a clinical level of evidence (LoE) and/or entailed a feasible study enrollment and were thus considered highly actionable. Sixteen recommendations, of which seven were highly actionable, were issued only on the basis of WES results (five own, two previous WES). Three out of those seven recommendations and one additional recommendation based on a previous large panel were related to complex molecular biomarkers such as homologous recombination deficiency or high tumor mutational burden, with poly (ADP-ribose) polymerase inhibitors or checkpoint inhibitors as recommended treatment. As expected, a higher proportion of the WES-only recommendations (63% versus 42% of recommendations overall) were based on non-clinical LoEs. One of eight recommendations implemented so far was based on biomarkers derived by WES only.

conclusionsIn our MTB, WES enabled some additional clinically highly actionable recommendations for selected patients, suggesting that some patients do benefit from additional WES. These recommendations were often related to complex biomarkers, which may in principle also be derived from larger panels. These findings should be re-investigated prospectively in larger cohorts.

Indexed as

Exome SequencingNeoplasmsAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedWhole Genome SequencingBiomarkers, Tumorbiomarkersmolecular tumor boardpanel sequencingWESwhole-exome sequencing

Identifiers

PMID41297163
PMCPMC12689208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.